Outlook Therapeutics, Inc. 8-K

What Happened
Outlook Therapeutics, Inc. announced a best‑efforts public offering of common stock and accompanying warrants, which closed on March 25, 2026. The company agreed to issue 20,000,000 shares of common stock and 20,000,000 warrants (one warrant per share) at a combined public offering price of $0.25 per share-plus-warrant, producing approximately $5.0 million in gross proceeds and about $4.0 million in net proceeds after placement agent fees and offering expenses. H.C. Wainwright & Co., LLC served as exclusive placement agent.

Key Details

• Offering size and price: 20,000,000 shares + 20,000,000 warrants; combined price $0.25; gross proceeds ≈ $5.0M; net proceeds ≈ $4.0M (after fees/expenses). Closed March 25, 2026.
• Warrant terms: initial exercise price $0.25; exercisable immediately; five‑year term; customary adjustments for splits/recaps; ownership exercise limits (4.99% or 9.99%, changeable with 61 days’ notice).
• Placement agent compensation: cash fee 7.0% of gross proceeds, management fee 1.0%, placement agent warrants to purchase 1,400,000 shares (7% of shares sold) at $0.3125 each (125% of offering price), plus reimbursed legal/clearing/expense allowances.
• Contractual limits: company agreed to certain offering‑related sale restrictions and not to enter Variable Rate Transactions for one year after closing, subject to customary exceptions.

Why It Matters
This financing provides Outlook Therapeutics with immediate capital (≈$4.0M net) to support operations or development priorities but dilutes current shareholders due to the new shares and potential warrant exercises. The placement agent warrants and fee structure increase the total potential dilution and cost of the financing. Investors should note the warrants’ low exercise price relative to current market (if applicable), the five‑year exercise window, and the one‑year limitation on certain future financings, which may affect near‑term equity availability and capital strategy. A legal opinion from Cooley LLP regarding the issuance was included in the filing.